Two Onc Docs

This week’s episode will be focusing on gastrointestinal stromal tumors, known as GIST with a 2025 update. We will go over important details on the diagnosis, mutations, and treatment of local and metastatic GISTs.  

This week’s episode is also due for an update since it aired in 2022. Will be focusing on Hodgkin Lymphoma (HL), both classical and nodular lymphocyte-predominant. We will go into important details on the pathology, staging, Deauville scoring, and treatment for early stage/advanced stage as well as relapsed and refractory HL.

Today’s episode is focusing on what you need to know regarding Anal cancer. This was one of our first episodes back in 2022 so it is time for an updated episode! This will include the important details on risk factors, diagnostic work-up, staging and treatment of both localized and metastatic anal cancer.

This week’s episode will be on many exciting updates were announced at ESMO this October in Berlin from Oct 17-21, 2025, especially in bladder cancer, we continue to make such progress! We discuss key trials in NMIBC (POTOMAC), MIBC (KN-905, IMvigor-011), and metastatic urothelial carcinoma (FORAGER-1, DV + Toripalimab).

This week’s episode will be focusing on details of the hematology & oncology board exams, how we prepared the days leading up to our exam, and we cover some highly tested topics in both hematology & oncology. We wish the best of luck to everyone taking their boards this year!

This week’s episode will be focusing on Porphyrias…which is very timely since this week is HALLOWEEN and porphyrias are the diseases many people believe started the vampire legend! 

This week’s episode is part 3 of our breast cancer series, with a 2025 update focusing on metastatic breast cancer systemic therapies, toxicities, and supportive care considerations. 

This week’s episode will be focusing on treatment options for localized breast cancer with 2025 updates. We will go over important details on indications for adjuvant radiation, as well as therapies based on the ER/PR/HER-2 receptor status.

October marks Breast Cancer Awareness Month. We are providing 2025 update for our 3 part breast cancer episodes, in part 1 today we cover an introduction on breast cancer screening, prevention. 

This week’s episode will be focusing on Esophageal and Gastrosophageal Junction (GEJ) Cancer. We will go over important details on the risk factors, diagnosis, and treatment for both localized and metastatic esophageal cancer.

This week’s episode will be focusing on Immune Thrombocytopenia Purpura ( ITP).   We will go all the important details on causes, mechanism, diagnosis and treatment. The last time we covered this topic was in Sept 2022, and this comes up ALL the time in heme consults, and there will definitely be board review questions. It may also be tested on IM boards.

This week’s episode will be an update on Bone Sarcomas. We will go over the important details on diagnosis, staging, subtypes and treatment of a few bone sarcomas. Just like Soft Tissue Sarcomas, these are RARE tumors encompassing 1% of all adult cancers and having multiple subtypes. They are more common in children, and most of our bone sarcoma recommendations that are testable are based on pedia...

This week’s episode will be focusing on soft tissue sarcomas. We last recorded this topic in 2023, and well we have some new FDA approvals and updates since then. We will go over the important details on the diagnosis, subtypes and treatment of a few soft tissue sarcomas. These are RARE tumors encompassing 1% of all adult cancers and having multiple subtypes that range from noncancerous tumors suc...

Today’s episode will focus on an update for commonly tested Thrombotic microangiopathies (TMA) such as Thrombotic Thrombocytopenic Purpura (TTP). This will include the high yield facts on mechanism, presentation, diagnostic work-up, and treatment of TTP, and also discuss Hemolytic Uremic Syndrome (HUS), and atypical HUS.

This week’s episode will be focusing on Gastric Adenocarcinoma. We will go over all the important details on risk factors, diagnostic work-up, staging and treatment for both local regional disease and metastatic disease with updates in 2025 since we last covered this topic in 2023.

We are updating another important GYN ONC topic: endometrial (uterine) cancer. We will go over all the important details on the risk factors, presentation, diagnosis, staging & treatment options. We will also cover rare uterine malignancies at the end of the episode.

Today’s episode we will cover 2025 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

Today’s episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options. 

This week’s episode will be focusing on Cervical Cancer with some updates since we last released this topic in 2022. We will go over important details on prevention, risk factors, diagnosis & treatment.

This week’s episode is an update on a must-know topics both for new fellows & residents. We will go over clinically important oncologic emergencies including brain metastases, hypercalcemia of malignancy, cord compression and SVC syndrome. 

This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025,  the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA. 

This week’s episode will be focusing on how to prepare for the start of heme/onc fellowship!  We will go over some general advice on how to succeed, study tips and resources we used throughout fellowship as well as some tips on how to stay academically productive during training if you are planning for an academic career.

This week’s episode will be focusing on one of the 2025 plenary sessions: SERENA-6, Camizestrant, a novel selective estrogen receptor degrader (SERD) + CDK 4/6i for tx of emergent ESR1 during 1L endocrine-based therapy + ahead of progression in stage 4 HR+/Her-2 negative breast cancer. We discuss the trial design, endpoints, results, safety concerns, and how it fits into current practice.

This week’s episode will be focusing on Ovarian Cancer with 2025 updates since we last covered this topic in 2022. We will go over all important details on the risk factors, presentation, diagnosis, staging & treatment options for both localized and metastatic disease. 

This week’s episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others.